Research programme: Zika virus vaccine - Emergent BioSolutions

Latest Information Update: 15 Sep 2016

Price : ^*

* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

Originator Unknown
Developer Emergent BioSolutions
Class Synthetic vaccines; Zika virus vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Preclinical Zika virus infection

Most Recent Events

04 Aug 2016 Preclinical trials in Zika virus infection in USA (unspecified route)
27 Jun 2016 Emergent BioSolutions receives a task order from the Biomedical Advanced Research and Development Authority for the development of a Zika virus vaccine

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.